View More View Less
  • 1 Szent Lázár Megyei Kórház, Salgótarján, Füleki út 54–56., 3100
  • 2 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest

Absztrakt:

A szérumalbuminszint csökkenése figyelhető meg gyulladásos folyamatokban. A helyileg előrehaladott vagy áttétes rosszindulatú daganatokban a szérumalbuminszint ugyancsak csökken, az alultápláltság fennállásától függetlenül. A csökkent albuminszint befolyásolhatja a terápia eredményeit is (például gyógyszerek farmakokinetikája, mellékhatások mértéke). Kiterjedt szakirodalmi adat és gyakorlati tapasztalat bizonyítja a táplálásterápiában részesülő páciensek jobb prognózisát. A szerzők a fontosabb szakirodalmi adatok alapján összefoglalják azon vizsgálatokat, melyek a kiindulási szérumalbuminszint és a rosszindulatú daganatos betegségek prognózisa közötti szoros összefüggést feltárták. Orv Hetil. 2018; 159(3): 96–106.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Nazha B, Moussaly E, Zaarour M, et al. Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate? World J Gastrointest Surg. 2015; 7: 370–377.

  • 2

    Schmid M, Schindler R, Weigand K, et al. Is albumin synthesis regulated by the colloid osmotic pressure? Effect of albumin and dextran on albumin and total protein synthesis in isolated rat hepatocytes. Klin Wochenschr. 1986; 64: 23–28.

  • 3

    Seaton K. Albumin concentration controls cancer. J Natl Med Assoc. 2001; 93: 490–493.

  • 4

    Peters T. Metabolism: Albumin in the body. In: All about albumin: biochemistry, genetics and medical applications. Academic Press Limited, San Diego, CA, 1996; p. 232.

  • 5

    Barber MD, Ross, JA, Fearon KC. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer 1999; 35: 106–110.

  • 6

    McMillan DC, Watson WS, O’Gorman P, et al. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001; 39: 210–213.

  • 7

    Deme D, Telekes A. Prognostic importance of plasma C-reactive protein (CRP) in oncology. [A C-reaktív protein (CRP) plazmaszintjének prognosztikai jelentősége az onkológiában.] Orv Hetil. 2017; 158: 243–256. [Hungarian]

  • 8

    Ahmad J, Grimes N, Farid S, et al. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2014; 13: 474–481.

  • 9

    Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer 2013; 13: 158.

  • 10

    Chang Y, An H, Xu L, et al. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br J Cancer 2015; 113: 626–633.

  • 11

    Hutterer GC, Stoeckigt C, Stojakovic T, et al. Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma. Urol Oncol. 2014; 32: 1041–1048.

  • 12

    Szkandera J, Gerger A, Liegl-Atzwanger B, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer 2014; 135: 362–370.

  • 13

    Cai W, Zhang J, Chen Y, et al. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma. Chin J Cancer 2017; 36: 47.

  • 14

    Deme D, Telekes A. Prognostic importance of lactate dehydrogenase (LDH) in oncology. [A laktátdehidrogenáz (LDH) prognosztikai jelentősége az onkológiában.] Orv Hetil. 2017; 158: 1977–1988. [Hungarian]

  • 15

    Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005; 54: 419–425.

  • 16

    Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach – the ALBI grade. J Clin Oncol. 2015; 33: 550–558.

  • 17

    Dirican N, Dirican A, Anar C, et al. A new inflammatory prognostic index, based on C-reactive protein, the neutrophil to lymphocyte ratio and serum albumin is useful for predicting prognosis in non-small cell lung cancer cases. Asian Pac J Cancer Prev. 2016; 17: 5101–5106.

  • 18

    Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J. 2010, 9: 69.

  • 19

    McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013; 39: 534–540.

  • 20

    Partridge M, Fallon M, Bray C, et al. Prognostication in advanced cancer: a study examining an inflammation-based score. J Pain Symptom Manage. 2012; 44: 161–167.

  • 21

    Li MX, Bi XY, Li ZY, et al. Prognostic role of Glasgow Prognostic Score in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2015; 94: e2133.

  • 22

    Petrelli F, Barni S, Coinu A, et al. The Modified Glasgow Prognostic Score and survival in colorectal cancer: A pooled analysis of the literature. Rev Recent Clin Trials 2015; 10: 135–141.

  • 23

    Chen Z, Shao Y, Wang K. Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysis. Onco Targets Ther. 2016; 9: 6701–6710.

  • 24

    Miao Y, Li S, Yan Q, et al. Prognostic significance of preoperative prognostic nutritional index in epithelial ovarian cancer patients treated with platinum-based chemotherapy. Oncol Res Treat. 2016; 39: 712–719.

  • 25

    Win T, Sharples L, Groves AM, et al. Predicting survival in potentially curable lung cancer patients. Lung 2008; 186: 97–102.

  • 26

    Ma XL, Zhou JY, Gao XH, et al. Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma. Clin Chim Acta 2016; 462: 15–22.

  • 27

    Lien YC, Hsieh CC, Wu YC, et al. Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardia. J Gastrointest Surg. 2004; 8: 1041–1048.

  • 28

    Oñate-Ocaña LF, Aiello-Crocifoglio V, Gallardo-Rincon D, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007; 14: 381–389.

  • 29

    Heys SD, Walker LG, Deehan DJ, et al. Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb. 1998; 43: 163–168.

  • 30

    McMillan DC, Crozier JE, Canna K, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007; 22: 881–886.

  • 31

    Zheng RR, Huang XW, Liu WY, et al. Nomogram predicting overall survival in operable cervical cancer patients. Int J Gynecol Cancer 2017; 27: 987–993.

  • 32

    Gupta D, Lammersfeld CA, Vashi PG, et al. Is serum albumin an independent predictor of survival in ovarian cancer? Clin Ovarian Cancer 2009; 2: 52–56.

  • 33

    Clark TG, Stewart ME, Altman DG, et al. A prognostic model for ovarian cancer. Br J Cancer 2001; 85: 944–952.

  • 34

    Barreto-Andrade JC, Medina-Franco H. Serum albumin is an independent prognostic factor for survival in soft tissue sarcomas. Rev Invest Clin. 2009; 61: 198–204.

  • 35

    Kim HL, Belldegrun AS, Freitas DG, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol. 2003; 170: 1742–1746.

  • 36

    Yap NY, Ng KL, Ong TA, et al. Clinical prognostic factors and survival outcome in renal cell carcinoma patients – a Malaysian single centre perspective. Asian Pac J Cancer Prev. 2013; 14: 7497–7500.

  • 37

    Lis CG, Grutsch JF, Vashi PG, et al. Is serum albumin an independent predictor of survival in patients with breast cancer? J Parenter Enteral Nutr. 2003; 27: 10–15.

  • 38

    Hou JY, Aparo S, Ghalib M, et al. Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: A single institution experience from 1999 to 2010. Gynecol Oncol. 2013; 131: 163–168.

  • 39

    Fox P, Hudson M, Brown C, et al. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer 2013; 109: 147–153.

  • 40

    Hwang EC, Hwang IS, Yu HS, et al. Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer. Jpn J Clin Oncol. 2012; 42: 955–960.

  • 41

    Linton A, Pond G, Clarke S, et al. Glasgow Prognostic Score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer 2013; 11: 423–430.

  • 42

    Shibutani M, Maeda K, Nagahara H, et al. Prognostic significance of the preoperative ratio of C-reactive protein to albumin in patients with colorectal cancer. Anticancer Res. 2016; 36: 995–1001.

  • 43

    Maretty-Nielsen K. Prognostic factors in soft tissue sarcoma. Population-based studies on comorbidity, biomarkers, and methodological aspects. Dan Med J. 2014; 61: B4957.

  • 44

    Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113: 1271–1276.

  • 45

    Nieken J, Mulder NH, Buter J, et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 1995; 86: 900–905.

  • 46

    Cengiz O, Kocer B, Sürmeli S, et al. Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med Sci Monit. 2006; 12: CR240–CR247.

  • 47

    Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004; 17: 432–437.

  • 48

    Babson AL, Winnick T. Protein transfer in tumor-bearing rats. Cancer Res. 1954; 14: 606–611.

  • 49

    Fearon KC, Falconer JS, Slater C, et al. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann Surg. 1998; 227: 249–254.

  • 50

    Don BR, Kaysen GA. Assessment of inflammation and nutrition in patients with end-stage renal disease. J Nephrol. 2000; 13: 249–259.

  • 51

    Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340: 448–454.

  • 52

    Castell JV, Gomez-Lechon MJ, David M, et al. Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179–1186.

  • 53

    Chojkier M. Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. J Clin Gastroenterol. 2005; 39(4 Suppl 2): S143–S146.

  • 54

    Fanali G, di Masi A, Trezza V, et al. Human serum albumin: from bench to bedside. Mol Aspects Med. 2012; 33: 209–290.

  • 55

    Vaz J, Ansari D, Sasor A, et al. SPARC: a potential prognostic and therapeutic target in pancreatic cancer. Pancreas 2015; 44: 1024–1035.

  • 56

    Cichota LC, Moresco RN, Duarte MM, et al. Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal. 2008; 22: 1–5.

  • 57

    Roy D, Quiles J, Gaze DC, et al. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006; 92: 113–114.

  • 58

    Fidan E, Mentese A, Kavgaci H, et al. Increased ischemia-modified albumin levels in patients with gastric cancer. Neoplasma 2012; 59: 393–397.

  • 59

    Ellidag HY, Bulbuller N, Eren E, et al. Ischemia-modified albumin: could it be a new oxidative stress biomarker for colorectal carcinoma? Gut Liver 2013; 7: 675–680.

  • 60

    Da Silveira RA, Hermes CL, Almeida TC, et al. Ischemia-modified albumin and inflammatory biomarkers in patients with prostate cancer. Clin Lab. 2014; 60: 1703–1708.

  • 61

    Ellidag HY, Eren E, Aydin O, et al. Ischemia modified albumin levels and oxidative stress in patients with bladder cancer. Asian Pac J Cancer Prev. 2013; 14: 2759–2763.

  • 62

    Satoh M, Kotani K, Gugliucci A, et al. Correlation of ischemia-modified albumin with SOFA and APACHE II scores in preoperative patients with colorectal cancer. Sci World J. 2014; 2014: 959075.

  • 63

    Ma Y, Kang W, Bao Y, et al. Clinical Significance of ischemia-modified albumin in the diagnosis of doxorubicin-induced myocardial injury in breast cancer patients. PLoS ONE 2013; 8: e79426.

  • 64

    Magyar K, Tóthfalusi L. Fate of drugs in the human body. Pharmacokinetics. In: Gyires K, Fürst Zs. (eds.) Principles of pharmacology. [A gyógyszerek sorsa a szervezetben. Farmakokinetika. In: Gyires K, Fürst Zs. (szerk.) A farmakológia alapjai.] Medicina Könyvkiadó, Budapest, 2011; pp. 67–68. [Hungarian]

  • 65

    Nicholas HG, Holford MB. Pharmacokinetics & Pharmacodynamics: Rational Dosing & the Time Course of Drug Action. In: Katzung BG, Masters SB, Trevor AJ. (eds.) Basic & Clinical Pharmacology. 12th edn. McGraw-Hill Companies, Inc., San Fancisco, CA, 2012; p. 49.

  • 66

    Buxton IL, Benet LZ. Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination. In: Brunton LL. (ed.) Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th edn. McGraw-Hill Companies, Inc., San Fancisco, CA, 2011; p. 43.

  • 67

    Kovács P, Kralovánszky J, Kovács G, et al. Pharmacokinetics. In: Jeney A, Kralovánszky J. (eds.) Oncopharmacology. [Farmakokinetika. In: Jeney A, Kralovánszky J. (szerk.) Onkofarmakológia.] Medicina Könyvkiadó, Budapest, 2009; p. 189. [Hungarian]

  • 68

    Chen N, Li Y, Ye Y, et al. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol. 2014; 54: 1097–1107.

  • 69

    Vincent JL, Russell JA, Jacob M, et al. Albumin administration in the acutely ill: what is new and where next? Crit Care 2014; 18: 231.

  • 70

    Vincent JL, Dubois MJ, Navickis RJ, et al. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg. 2003; 237: 319–334.

  • 71

    Kaya SO, Akcam TI, Ceylan KC, et al. Is preoperative protein-rich nutrition effective on postoperative outcome in non-small cell lung cancer surgery? A prospective randomized study. J Cardiothorac Surg. 2016; 11: 14.

  • 72

    Qiu M, Zhou YX, Jin Y, et al. Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy. Support Care Cancer 2015; 23: 1933–1939.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Sep 2020 0 16 36
Oct 2020 0 23 39
Nov 2020 0 25 44
Dec 2020 0 20 60
Jan 2021 0 26 102
Feb 2021 0 13 149
Mar 2021 0 4 39